Share
Allen Guo, Whitney Winters & Michael Vreeland
ProBio, a global leader in contract development and manufacturing (CDMO) services, announced the appointment of Allen Guo as Chief Executive Officer (CEO), Whitney Winters as Senior Vice President of U.S. Business Development, and Michael Vreeland as U.S. Site Head and Interim Head of U.S. Process Development. These leadership changes reinforce ProBio’s commitment to accelerating life-changing therapies for biotech and pharmaceutical companies worldwide.
Allen Guo, who joined ProBio in 2021, brings 16 years of leadership experience from Janssen, Lonza, Becton Dickinson, and Patheon. Under his guidance, ProBio’s business development team has significantly contributed to the company’s revenue by supporting end-to-end projects from discovery to the pre-commercial Biologics License Application (BLA) stage. His strategic leadership has been instrumental in securing key projects and fostering high-performing teams.
Whitney Winters, previously Vice President of Commercial Excellence at ProBio, has been promoted to Senior Vice President of U.S. Business Development. With 17 years of sales and marketing experience, including a successful tenure at West Pharmaceutical Services, she will oversee business development and marketing efforts, driving commercial strategy and expanding ProBio’s presence in the U.S. market.
Michael Vreeland takes on the role of U.S. Site Head and Interim Head of Process Development, leading operations at ProBio’s state-of-the-art Hopewell, New Jersey, manufacturing facility. With over 16 years of cGMP manufacturing experience from Curia, Thermo Fisher Scientific, and Sanofi Pasteur, he brings deep expertise in plasmid DNA, viral vectors, biologics manufacturing, and process development.
Dr. Li Chen, ProBio’s previous CEO, will remain as a consultant to ensure a seamless leadership transition.
Founded in 2020, ProBio has supported over 108 global IND clearances and remains dedicated to providing cutting-edge CDMO solutions for biologics and advanced therapies. These appointments further strengthen ProBio’s position as an innovative, customer-centric CDMO committed to advancing healthcare solutions for a better future.
